Assessing the Clinical and Economic Burden of Coronary Artery Disease: 1986-1998

Medical Care

Volumn 39, Issue 8, 2001, Pages 824-835

  Eisenstein, Eric L ^a,c   Shaw, Linda K ^a   Anstrom, Kevin J ^a   Nelson, Charlotte L ^a   Hakim, Zafar ^b   Hasselblad, Vic ^a   Mark, Daniel B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Roche Global Pharmacoeconomic Res   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Burden of illness; Coronary artery disease; Cost analysis; Costs

Indexed keywords

AGED; ARTICLE; CORONARY ARTERY DISEASE; COST OF ILLNESS; DRUG COST; ECONOMICS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH SERVICE; HEART INFARCTION; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; REGRESSION ANALYSIS; STATISTICS; SURVIVAL RATE; UNITED STATES; UNSTABLE ANGINA PECTORIS; UTILIZATION REVIEW;

AGED; ANGINA, UNSTABLE; CORONARY DISEASE; COST OF ILLNESS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITAL COSTS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORTH CAROLINA; PATIENT READMISSION; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0035430627     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200108000-00008     Document Type: Article

References (36)

1. Califf RM, Eisenstein EL. Cost-effectiveness of therapy for acute ischemic heart disease. In: Talley JD, ed. Cost-effective Diagnosis and Treatment of Coronary Artery Disease. New York, NY: Igaku-Shoin; 1997:139-167.
2. Mark DB. Assessment of prognosis in patients with coronary artery disease. In: Roubin GS, Califf RM, O'Neill WW, Phillips HR III, Stack RS, eds. Interventional Cardiovascular Medicine: Principles and Practice. New York, NY: Churchill Livingstone; 1994:165-185.
3. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993;22:1228-1241.
4. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Agency for Health Care Policy and Research 1994:94-0682.
5. Mark DB, Topol EJ. Chronic coronary artery disease. In: Talley JD, Mauldin PD, Becker ER, eds. Cost Effective Diagnosis and Treatment of Coronary Artery Disease. Baltimore, MD: Williams & Wilkins; 1997:168-177.
6. Archibald N, Jones RH. Guidelines for treatment of unstable angina. In: Califf RM, ed. Acute myocardial infarction and other acute ischemic syndromes. Philadelphia, PA: Current Medicine; 1996:14.1-14.22.
7. Franzosi MG, Santoro E, De Vita C, et al. Ten year follow up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiono per lo Sudio della Sorpavivenza nell'infarto-1 study. Circulation 1998;98: 2659-2665.
8. Kannel WB, Manning F. Natural history of angina pectoris in the Framingham study. Am J Cardiol 1972;29:154-163.
9. Harris PJ, Lee KL, Harrell FE Jr, et al. Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. Circulation 1980;62:718-726.
10. Orencia A, Bailey K, Yawn BP, et al. Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden expected death. JAMA 1993;269:2392-2397.
11. Rosengren A, Wilhelmsen L, Hagman M, et al. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16 year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Intern Med 1998;244:495-505.
12. Galatius S, Launberg J, Mortensen LS, et al. 5993 survivors of suspected myocardial infarction. Ten year incidence of later myocardial infarction and subsequent mortality. Eur Heart J 1998;19:564-569.
13. Sigurdsson E, Sigfusson N, Agnarsson U, et al. Long-term prognosis of different forms of coronary heart disease: the Reykjavik study. Int J Epidemiol 1995;24:58-68.
14. Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432-440.
15. Hemenway D, Sherman H, Mudge GH, et al. Comparative costs versus symptomatic and employment benefits of medical and surgical treatment of stable angina pectoris. Med Care 1985;23:133-141.
16. Kuntz KM, Tsevat J, Goldman L, et al. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957-965.
17. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:110-115.
18. Sagmeister M, Gessner U, Oggier W, et al. An economic analysis of ischemic heart disease in Switzerland. Eur Heart J 1997;18:1102-1109.
19. Harris PJ, Harrell FE Jr, Lee KL, et al. Survival in medically treated coronary artery disease. Circulation 1979;60:1259-1269.
20. Califf RM, Harrell FE Jr, Lee KL, et al. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective. JAMA 1989;261:2077-2086.
21. Rosati RA, McNeer JF, Starmer CF, et al. A new information system for medical practice. Arch Intern Med 1975;135:1017-1024.
22. Fortin DF, Califf RM, Pryor DB, et al. The way of the future redux. Am J Cardiol 1995;76:1177-1182.
23. Mark DB, Nelson CL, Califf RM, et al. The continuing evolution of therapy for coronary artery disease: initial results from the era of coronary angioplasty. Circulation 1994;89:2015-2025.
24. Mark DB, Granger CB, Ellis SG, et al. Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: Results from the GUSTO II randomized trial. [abstr]. Circulation 1996;94:168A.
25. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
26. Nelson CL, Eisenstein EL, Shaw LK, et al. Estimating life-expectancy in post-acute coronary syndromes: the importance of combined survival models. [abstr]. Int'l Meeting of ISPOR May 24, 1999; Crystal City, Virginia.
27. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford U Press, 1996.
28. Anonymous. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Medical Economics Company; 1997.
29. Avorn J, Monette J, Lacour A. Persistence of use of lipid lowering medications: a cross-national study. JAMA 1998;279:1458-1462.
30. Smith SC. What is happening in the real world in lipid therapy and is it appropriate? The need for a paradigm shift Value in Health 1998;1:204-207.
31. Anonymous. AWP Overstates actual pharmacy invoice cost for brand name drugs by average of 18.3% nationwide HHS IG concludes; generic AWP overstates by 42.5%. FDC Reports: Prescription Pharmaceuticals and Biotechnology 1997; January 13:7.
32. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000;87:329-343.
33. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. J Am Stat Asso 1952;47:663-685.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958;53:457-481.
35. American Heart Association. 2001 Heart and Stroke Statistical Update. American Heart Association. 2001.
36. Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990; the effect of secular trends in risk factors and treatment:JAMA1997;277:535-542.